Eris Lifesciences Limited has announced a significant corporate action that could reshape its ownership structure in Swiss Parenterals Limited. The pharmaceutical company's board is set to meet on November 24, 2025, to deliberate on a preferential share issue aimed at acquiring the remaining stake in its subsidiary.

Key Points of the Announcement

• Board Meeting Date: November 24, 2025
• Primary Agenda: Consider issuing equity shares through preferential allotment
• Purpose: To acquire the remaining 30% stake in Swiss Parenterals Limited
• Additional Consideration: Convening an Extraordinary General Meeting (EGM) for shareholder approval

Details of the Proposed Action

The board meeting will focus on a proposal to issue equity shares of Eris Lifesciences through a preferential allotment. This issuance is intended to be for consideration other than cash, suggesting a share swap arrangement might be under consideration for the acquisition of Swiss Parenterals' remaining equity.

Regulatory Compliance

The company has emphasized that the proposed preferential issue will be in accordance with:

• The Companies Act, 2013 (as amended)
• SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)
• SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (as amended)
• Other applicable laws and regulations

Shareholder Approval Process

If the board approves the preferential issue, Eris Lifesciences plans to seek shareholder approval through either:

1. An Extraordinary General Meeting (EGM), or
2. A postal ballot process

This step is crucial for proceeding with the proposed share issuance and subsequent acquisition.

Implications and Outlook

The potential acquisition of the remaining 30% stake in Swiss Parenterals Limited signifies Eris Lifesciences' strategic move towards consolidating its ownership in the subsidiary. This action, if approved and executed, could lead to:

1. Enhanced control over Swiss Parenterals' operations
2. Potential synergies and operational efficiencies
3. A possible impact on Eris Lifesciences' capital structure and shareholding pattern

Investors and market watchers will be keenly awaiting the outcome of the November 24 board meeting and any subsequent announcements regarding the terms of the preferential issue and acquisition details.

It's important to note that the proposed actions are subject to various regulatory and statutory approvals, as well as shareholder consent. The company will likely provide more details following the board meeting and as the process unfolds.

Eris Lifesciences , a prominent player in the pharmaceuticals sector, has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results in a meeting held on November 12, 2025.

Financial Performance

For the quarter ended September 30, 2025 (Q2 FY26), Eris Lifesciences reported the following key financial metrics:

The company demonstrated strong growth across all major financial indicators. Notably, the net profit saw a substantial increase compared to the same quarter in the previous year.

Operational Highlights

• The Operating Profit Margin (OPM) improved to 36.2%, showing a significant increase of 40.36% compared to the same period last year.
• Other income for the quarter stood at ₹22.70 crore, representing a 336.54% increase year-over-year.
• The company's expenses rose by 8.70% to ₹362.30 crore, which is notably lower than the revenue growth rate, indicating improved operational efficiency.

Board Approvals and Corporate Actions

In addition to the financial results, the Board of Directors made several key decisions:

1. Director Reappointments:

   • Mr. Krishnakumar Vaidyanathan has been recommended for reappointment as Whole Time Director for a 5-year term from September 1, 2026, to August 31, 2031.
   • Ms. Kalpana Unadkat has been recommended for reappointment as Independent Director for a 5-year term from January 5, 2026, to January 4, 2031.

2. Employee Stock Option Scheme: The company issued 50,985 ordinary shares under its Employee Stock Option Scheme 2021 during the half-year period. This action has increased the paid-up share capital to ₹13.62 crore.

Business Segment

Eris Lifesciences continues to operate primarily in the pharmaceuticals business segment. The financial performance, coupled with strategic board decisions, may influence the company's operations in the coming years.

The reappointment of key directors suggests a focus on maintaining leadership continuity, which may contribute to the company's long-term strategic planning and execution.